Abstract
The rapidly increasing elderly population poses a major challenge for future health-care systems. Neurological diseases in older persons are particularly common and coexist with other clinical conditions.
This is not surprising given that, for example, even patients with Alzheimer Disease (AD) could have relevant extrapyramidal signs at the moment of the diagnosis with motor signs having more negative prognostic value. Longitudinal studies conducted on Parkinson Disease (PD) showed that, after 20 years, dementia is not only present in almost all survivors but is also the main factor influencing nursing home admission.
Recently, it has been reported the importance of Comprehensive Geriatric Assessment (CGA: comprehensive evaluation of cognition, depressive symptoms, mobility and functional assessment) as a tool reducing morbidity in frail older patients admitted to any acute hospital unit. The CGA should be considered as a technological device, for physicians who take care of older persons affected by overlapping neurological diseases. CGA is an extraordinary and cost effective instrument even in patients with advanced neurological diseases where allows to collect valuable information for an effective plan of management.
Keywords: Neurological disease, older persons, mobility limitations, parkinsonism.
Current Pharmaceutical Design
Title:Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Volume: 20 Issue: 19
Author(s): Fulvio Lauretani, Gian Paolo Ceda, Pio Pelliccioni, Livia Ruffini, Anna Nardelli, Antonio Cherubini and Marcello Maggio
Affiliation:
Keywords: Neurological disease, older persons, mobility limitations, parkinsonism.
Abstract: The rapidly increasing elderly population poses a major challenge for future health-care systems. Neurological diseases in older persons are particularly common and coexist with other clinical conditions.
This is not surprising given that, for example, even patients with Alzheimer Disease (AD) could have relevant extrapyramidal signs at the moment of the diagnosis with motor signs having more negative prognostic value. Longitudinal studies conducted on Parkinson Disease (PD) showed that, after 20 years, dementia is not only present in almost all survivors but is also the main factor influencing nursing home admission.
Recently, it has been reported the importance of Comprehensive Geriatric Assessment (CGA: comprehensive evaluation of cognition, depressive symptoms, mobility and functional assessment) as a tool reducing morbidity in frail older patients admitted to any acute hospital unit. The CGA should be considered as a technological device, for physicians who take care of older persons affected by overlapping neurological diseases. CGA is an extraordinary and cost effective instrument even in patients with advanced neurological diseases where allows to collect valuable information for an effective plan of management.
Export Options
About this article
Cite this article as:
Lauretani Fulvio, Ceda Paolo Gian, Pelliccioni Pio, Ruffini Livia, Nardelli Anna, Cherubini Antonio and Maggio Marcello, Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons, Current Pharmaceutical Design 2014; 20 (19) . https://dx.doi.org/10.2174/13816128113196660687
DOI https://dx.doi.org/10.2174/13816128113196660687 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of Drugs in Cells and Tissues by NMR Spectroscopy
Current Topics in Medicinal Chemistry Magnetic Resonance Imaging in Alzheimer’s Disease: from Diagnosis to Monitoring Treatment Effect
Current Alzheimer Research Matrix Metalloproteinases in Vascular Disease - A Potential Therapeutic Target?
Current Vascular Pharmacology Pharmacological Intervention at Ionotropic Glutamate Receptor Complexes
Current Pharmaceutical Design Alcohol Consumption, Dementia and Cognitive Decline: An Overview of Systematic Reviews
Current Clinical Pharmacology Neuroprotective Effects of Low-dose Lithium in Individuals at Ultra-high Risk for Psychosis. A Longitudinal MRI/MRS Study
Current Pharmaceutical Design Wnt/β-Catenin Signaling in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Role of Artificial Intelligence Techniques (Automatic Classifiers) in Molecular Imaging Modalities in Neurodegenerative Diseases
Current Alzheimer Research Applications of Positron Emission Tomography in Neuropsychiatric Pharmaceutical Drug Development
Current Radiopharmaceuticals Induction of Molecular Chaperones as a Therapeutic Strategy for the Polyglutamine Diseases
Current Pharmaceutical Biotechnology Ectonucleotidases and Nucleotide/Nucleoside Transporters as Pharmacological Targets for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Flavones from Root of Scutellaria Baicalensis Georgi: Drugs of the Future in Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Recent Developments in the Treatment of Alcoholic Chronic Pancreatitis
Current Drug Abuse Reviews The Extra-Hematopoietic Role of Erythropoietin in Diabetes Mellitus
Current Diabetes Reviews Semantic Intrusions and Failure to Recover From Semantic Interference in Mild Cognitive Impairment: Relationship to Amyloid and Cortical Thickness
Current Alzheimer Research Quantitative Gait Disturbances in Older Adults with Cognitive Impairments
Current Pharmaceutical Design Metal Catalyzed Oxidation of Alpha-Synuclein – A Role for Oligomerization in Pathology?
Current Alzheimer Research Hypoxia Inducible Factor-1 as a Target for Neurodegenerative Diseases
Current Medicinal Chemistry Natural and Synthetic Inhibitors of Caspases: Targets for Novel Drugs
Current Drug Targets - CNS & Neurological Disorders Asymptomatic Carriers of Presenilin-1 E318G Variant Show no Cerebrospinal Fluid Biochemical Signs Suggestive of Alzheimer’s disease in a Family with Late-onset Dementia
Current Alzheimer Research